Expression patterns of RelA and c-mip are associated with different glomerular diseases following anti-VEGF therapy

Kidney International

Volumn 85, Issue 2, 2014, Pages 457-470

  Izzedine, Hassan ^a   Mangier, Melanie ^b,c   Ory, Virginie ^b,c   Zhang, Shao Yu ^b,c   Sendeyo, Kelhia ^b,c   Bouachi, Khedidja ^b,c,d   Audard, Vincent ^b,c,d   Péchoux, Christine ^e   Soria, Jean C ^f   Massard, Christophe ^f   Bahleda, Rastilav ^f   Bourry, Edward ^a   Khayat, David ^a   Baumelou, Alain ^a   Lang, Philippe ^b,c,d   Ollero, Mario ^b,c   Pawlak, Andre ^b,c   Sahali, Djillali ^b,c,d  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b INSERM U955   (France)

^c UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^d HENRI MONDOR HOSPITAL   (France)

^e INRA Institut National de la Recherche Agronomique   (France)

^f INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

anti VEGF; c mip; FSGS; MCNS; NF B; thrombotic microangiopathy

Indexed keywords

AFLIBERCEPT; ALPHA INTERFERON; ANTIHYPERTENSIVE AGENT; AXITINIB; BEVACIZUMAB; COMPLEMENT FACTOR H; CREATININE; ENZYME ANTIBODY; FIBRINOGEN; GEMCITABINE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMATINIB; MEMBRANE COFACTOR PROTEIN; NEUTROPHIL CYTOPLASMIC ANTIBODY; PLATINUM COMPLEX; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR C MIP; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; VON WILLEBRAND FACTOR CLEAVING PROTEINASE ANTIBODY;

ACUTE KIDNEY TUBULE NECROSIS; ADRENAL CANCER; ADULT; AGED; ANIMAL CELL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; C MIP GENE; CANCER RADIOTHERAPY; CAUSE OF DEATH; CLINICAL ARTICLE; COLORECTAL CANCER; COMPLEMENT ALTERNATIVE PATHWAY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; CYTOSKELETON; DIABETIC NEPHROPATHY; DRUG ACTIVITY; EMBRYO; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME ACTIVITY; ESOPHAGUS CANCER; FEMALE; FOCAL SEGMENTAL GLOMERULOPATHY; GENE; GENE OVEREXPRESSION; GLOMERULAR STRUCTURE; GLOMERULONEPHRITIS; GLOMERULOPATHY; HEMATURIA; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERTENSION; HYPOALBUMINEMIA; IMMUNOGLOBULIN A NEPHROPATHY; IN VITRO STUDY; IN VIVO STUDY; INTERSTITIAL NEPHRITIS; KIDNEY CARCINOMA; KIDNEY DISEASE; KIDNEY FAILURE; LUNG CANCER; MALE; MEMBRANOUS GLOMERULONEPHRITIS; METASTASIS POTENTIAL; MICROSCOPY; MINIMAL CHANGE NEPHROPATHY; MOUSE; MULTIPLE CYCLE TREATMENT; MUTATIONAL ANALYSIS; NEPHRECTOMY; NONHUMAN; OVARY CANCER; PATHOGENESIS; PODOCYTE; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEINURIA; RECTUM CANCER; RELA GENE; THROMBOTIC THROMBOCYTOPENIC PURPURA; TRANSCRIPTION INITIATION; UTERUS CANCER; VERY ELDERLY;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANIMALS; BASE SEQUENCE; BINDING SITES; BIOLOGICAL MARKERS; CARRIER PROTEINS; CASE-CONTROL STUDIES; CELL LINE; FEMALE; GENE EXPRESSION REGULATION; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; HYPERTENSION; KIDNEY DISEASES; KIDNEY GLOMERULUS; MALE; MICE; MICE, KNOCKOUT; MIDDLE AGED; MOLECULAR SEQUENCE DATA; NEPHROSIS, LIPOID; NIACINAMIDE; PHENYLUREA COMPOUNDS; PREDICTIVE VALUE OF TESTS; PROMOTER REGIONS, GENETIC; PROTEIN KINASE INHIBITORS; PROTEINURIA; RENAL INSUFFICIENCY; THROMBOTIC MICROANGIOPATHIES; TRANSCRIPTION FACTOR RELA; TRANSCRIPTION, GENETIC; TRANSFECTION; VASCULAR ENDOTHELIAL GROWTH FACTORS; YOUNG ADULT;

EID: 84895902363     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2013.344     Document Type: Article

References (48)

1. Muller-Deile J, Worthmann K, Saleem M et al. The balance of autocrine VEGF-A and VEGF-C determines podocyte survival. Am J Physiol Renal Physiol 2009; 297: F1656-F1667
2. Guan F, Villegas G, Teichman J et al. Autocrine VEGF-A system in podocytes regulates podocin and its interaction with CD2AP. Am J Physiol Renal Physiol 2006; 291: F422-F428
3. Ivy SP, Wick JY, Kaufman BM. An overview of small-molecule inhibitors of VEGFR signaling. Nat Rev Clin Oncol 2009; 6: 569-579
4. Kerbel RS. Tumor angiogenesis. N Engl J Med 2008; 358: 2039-2049
5. Maharaj AS, Saint-Geniez M, Maldonado AE et al. Vascular endothelial growth factor localization in the adult. Am J Pathol 2006; 168: 639-648
6. Neufeld G, Cohen T, Gengrinovitch S et al. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999; 13: 9-22
7. Shweiki D, Itin A, Soffer D et al. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992; 359: 843-845
8. Heinrich MC, Corless CL, Duensing A et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003; 299: 708-710
9. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342
10. Waller CF. Imatinib mesylate. Recent Results Cancer Res 2010; 184: 3-20
11. Homsi J, Daud AI. Spectrum of activity and mechanism of action of VEGF/PDGF inhibitors. Cancer Control 2007; 14: 285-294
12. Eremina V, Jefferson JA, Kowalewska J et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008; 358: 1129-1136
13. Mathieson PW. Minimal change nephropathy and focal segmental glomerulosclerosis. Semin Immunopathol 2007; 29: 415-426
14. Sanz AB, Sanchez-Nino MD, Ramos AM et al. NF-kappaB in renal inflammation. J Am Soc Nephrol 2010; 21: 1254-1262
15. Nowak DE, Tian B, Jamaluddin M et al. RelA Ser276 phosphorylation is required for activation of a subset of NF-kappaB-dependent genes by recruiting cyclin-dependent kinase 9/cyclin T1 complexes. Mol Cell Biol 2008; 28: 3623-3638
16. Zhong H, Voll RE, Ghosh S. Phosphorylation of NF-kappa B p65 by PKA stimulates transcriptional activity by promoting a novel bivalent interaction with the coactivator CBP/p300. Mol Cell 1998; 1: 661-671
17. Arun P, Brown MS, Ehsanian R et al. Nuclear NF-kappaB p65 phosphorylation at serine 276 by protein kinase A contributes to the malignant phenotype of head and neck cancer. Clin Cancer Res 2009; 15: 5974-5984
18. Izzedine H, Massard C, Spano JP et al. VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management. Eur J Cancer 2010; 46: 439-448
19. Roncone D, Satoskar A, Nadasdy T et al. Proteinuria in a patient receiving anti-VEGF therapy for metastatic renal cell carcinoma. Nat Clin Pract Nephrol 2007; 3: 287-293
20. Frangie C, Lefaucheur C, Medioni J et al. Renal thrombotic microangiopathy caused by anti-VEGF-Antibody treatment for metastatic renal-cell carcinoma. Lancet Oncol 2007; 8: 177-178
21. Izzedine H, Brocheriou I, Deray G et al. Thrombotic microangiopathy and anti-VEGF agents. Nephrol Dial Transplant 2007; 22: 1481-1482
22. Bollee G, Patey N, Cazajous G et al. Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib. Nephrol Dial Transplant 2009; 24: 682-685
23. Henke N, Schmidt-Ullrich R, Dechend R et al. Vascular endothelial cellspecific NF-kappaB suppression attenuates hypertension-induced renal damage. Circ Res 2007; 101: 268-276
24. Guzik TJ, Harrison DG. Endothelial NF-kappaB as a mediator of kidney damage: The missing link between systemic vascular and renal disease? Circ Res 2007; 101: 227-229
25. Takase O, Marumo T, Imai N et al. NF-kappaB-dependent increase in intrarenal angiotensin II induced by proteinuria. Kidney Int 2005; 68: 464-473
26. Yang JC, Haworth L, Sherry RM et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349: 427-434
27. Thakker GD, Hajjar DP, Muller WA et al. The role of phosphatidylinositol 3-kinase in vascular endothelial growth factor signaling. J Biol Chem 1999; 274: 10002-10007
28. Lamalice L, Houle F, Huot J. Phosphorylation of Tyr1214 within VEGFR-2 triggers the recruitment of Nck and activation of Fyn leading to SAPK2/p38 activation and endothelial cell migration in response to VEGF. J Biol Chem 2006; 281: 34009-34020
29. Gong C, Stoletov KV, Terman BI. VEGF treatment induces signaling pathways that regulate both actin polymerization and depolymerization. Angiogenesis 2004; 7: 313-321
30. Veron D, Reidy KJ, Bertuccio C et al. Overexpression of VEGF-A in podocytes of adult mice causes glomerular disease. Kidney Int 2010; 77: 989-999
31. Bertuccio C, Veron D, Aggarwal PK et al. Vascular endothelial growth factor receptor 2 direct interaction with nephrin links VEGF-A signals to actin in kidney podocytes. J Biol Chem 2011; 286: 39933-39944
32. Sison K, Eremina V, Baelde H et al. Glomerular structure and function require paracrine, not autocrine, VEGF-VEGFR-2 signaling. J Am Soc Nephrol 2010; 21: 1691-1701
33. Jin J, Sison K, Li C et al. Soluble FLT1 binds lipid microdomains in podocytes to control cell morphology and glomerular barrier function. Cell 2012; 151: 384-399
34. Echeverria V, Burgess S, Gamble-George J et al. Sorafenib inhibits nuclear factor kappa B, decreases inducible nitric oxide synthase and cyclooxygenase-2 expression, and restores working memory in APPswe mice. Neuroscience 2009; 162: 1220-1231
35. Zhang SY, Kamal M, Dahan K et al. c-mip impairs podocyte proximal signaling and induces heavy proteinuria. Sci Signal 2010; 3: Ra39
36. Sendeyo K, Audard V, Zhang SY et al. Upregulation of c-mip is closely related to podocyte dysfunction in membranous nephropathy. Kidney Int 2013; 83: 414-425
37. Fremeaux-Bacchi V, Moulton EA, Kavanagh D et al. Genetic and functional analyses of membrane cofactor protein (CD46) mutations in atypical hemolytic uremic syndrome. J Am Soc Nephrol 2006; 17: 2017-2025
38. Veyradier A, Obert B, Houllier A et al. Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: A study of 111 cases. Blood 2001; 98: 1765-1772
39. Tesch GH, Hill PA, Wei M et al. LF15-0195 prevents the induction and inhibits the progression of rat anti-GBM disease. Kidney Int 2001; 60: 1354-1365
40. Rangan GK, Tesch GH. Quantification of renal pathology by image analysis. Nephrology (Carlton) 2007; 12: 553-558
41. Tokuyasu KT. A technique for ultracryotomy of cell suspensions and tissues. J Cell Biol 1973; 57: 551-565
42. Mundel P, Reiser J, Zuniga Mejia Borja A et al. Rearrangements of the cytoskeleton and cell contacts induce process formation during differentiation of conditionally immortalized mouse podocyte cell lines. Exp Cell Res 1997; 236: 248-258
43. Beg AA, Sha WC, Bronson RT et al. Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-kappa B. Nature 1995; 376: 167-170
44. Thanos D, Maniatis T. The high mobility group protein HMG I(Y) is required for NF-kappa B-dependent virus induction of the human IFNbeta gene. Cell 1992; 71: 777-789
45. Kamal M, Valanciute A, Dahan K et al. C-mip interacts physically with RelA and inhibits nuclear factor kappa B activity. Mol Immunol 2009; 46: 991-998
46. Wells J, Farnham PJ. Characterizing transcription factor binding sites using formaldehyde crosslinking and immunoprecipitation. Methods 2002; 26: 48-56
47. Sahali D, Pawlak A, Le Gouvello S et al. Transcriptional and posttranscriptional alterations of IkappaBalpha in active minimal-change nephrotic syndrome. J Am Soc Nephrol 2001; 12: 1648-1658
48. Stein B, Rahmsdorf HJ, Steffen A et al. UV-induced DNA damage is an intermediate step in UV-induced expression of human immunodeficiency virus type 1, collagenase, c-fos, and metallothionein. Mol Cell Biol 1989; 9: 5169-5181